Neuro-Oncology Program

摘要-神经肿瘤学 根据美国国家癌症研究所2014年公布的数据， 在美国患有脑和其他神经系统癌症的人。恶性原发性脑肿瘤 是儿童和年轻人癌症死亡的最常见原因， 肾癌或黑素瘤。 神经肿瘤学项目是杜克最知名、最古老的癌症项目之一， 2017年庆祝成立80周年。第一个在杜克大学建立脑肿瘤研究和临床活动的人 是巴恩斯伍德霍尔博士，1937年从约翰霍普金斯大学来到杜克大学。神经肿瘤学项目 自2004年被指定为NCI综合癌症中心以来， 1972. 研究范围从最基础的科学到临床试验，涵盖各种重点领域，包括 基础和功能基因组学;建立一个世界级的生物储存库，包括4000多名成年人和 儿科脑肿瘤样本，80多个异种移植物和转基因模型，以重现人类疾病 和用于药物/试剂筛选;开发用于原发性和转移性CNS肿瘤的新型免疫疗法; 设计和执行I、II和III期临床试验;改善患者的生活质量和治疗 通过支持性护理临床试验获得的经验;以及分子流行病学和基因组研究， 恶性脑肿瘤的病因。这项研究是由神经肿瘤学项目的使命推动的 确定所有主要类型成人和儿童恶性脑肿瘤的病因和相关肿瘤生物标志物 肿瘤，并从创新和预测模型系统的筛选中发明和转化新的治疗方法 到人类测试和开发的开创性临床试验。综合肿瘤的维护 下一代神经肿瘤学家的生物储备和培训确保了 神经肿瘤学计划及其研究目标。 该计划是由27个主要成员和6个次要成员从广泛的8个 杜克大学内的不同部门和1所学校和研究所。小学直接供资共计 计划成员为1190万美元，其中610万美元是同行评审的，包括来自NCI的370万美元。从2014年到2018年， 项目成员在PubMed引用的同行评审期刊上发表了415篇论文。其中，33% 其中36%是方案内合作的结果，36%是方案间合作的结果。期间 在目前的资助期内，该计划招募了948名受试者参加所有试验，736名参与干预性试验，551名参与 治疗试验

ABSTRACT – NEURO-ONCOLOGY PROGRAM According to data published by the National Cancer Institute in 2014, there were an estimated 162,341 people living with brain and other nervous system cancer in the United States. Malignant primary brain tumors are the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. The Neuro-Oncology Program is one of the most well-known and oldest cancer programs at Duke, having celebrated its 80th anniversary in 2017. The first to establish brain tumor research and clinical activities at Duke was Dr. Barnes Woodhall, who came to Duke from Johns Hopkins in 1937. The Neuro-Oncology Program has been a premier program within the DCI since its initial designation as an NCI Comprehensive Cancer Center in 1972. Research ranges from the most basic science to clinical trials encompassing various focus areas including basic and functional genomics; establishment of a world class biorepository including more than 4000 adult and pediatric brain tumor samples, more than 80 xenografts and transgenic models to recapitulate human disease and for drug/agent screening; development of novel immunotherapies for primary and metastatic CNS tumors; design and execution of Phase I, II, and III clinical trials; improving patient’s quality of life and treatment experience through Supportive Care clinical trials; and molecular epidemiology and genomic studies to identify causation factors of malignant brain tumors. This research is driven by the Neuro-Oncology Program’s mission to identify the cause and relevant tumor biomarkers in all major types of adult and childhood malignant brain tumors and to invent and translate novel therapeutics from screening in innovative and predictive model systems to human testing and development in pioneering clinical trials. Maintenance of the comprehensive tumor biorepository and training of the next generation of neuro-oncologists ensures the continuing development of the Neuro-Oncology Program and its research goals. The Program is comprised of 27 primary members and 6 secondary members from a wide spectrum of 8 different departments and 1 school and institutes within Duke University. Total direct funding for primary Program members is $11.9M of which $6.1M is peer reviewed, including $3.7M from the NCI. From 2014-2018, Program members published 415 papers in peer-reviewed journals cited in PubMed. Of these publications, 33% are the result of intra-programmatic collaborations and 36% are due to inter-programmatic collaborations. During the current grant period, the program enrolled 948 subjects to all trials, 736 to interventional trials, and 551 to treatment trials.